We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Premaitha | LSE:NIPT | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.10 | 9.00 | 9.20 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/1/2017 09:25 | elrico - fwiw I agree 100%, without an authenticated source it's nothing more than an anonymous post on a BB. Hopefully reality is not too far away but til the approaching Court case precipitates action it's more of the doldrums imho. | gooosed | |
19/1/2017 09:20 | Premaitha takeover, bring it on. 50p plus please. | timojelly | |
19/1/2017 01:13 | yes, nice and tight!! and it's not what I'm telling you, it's what the good man at Hardman is telling us and I have no reason to doubt him. As I said he has researched this in detail and must be very very sure of himself to actually put that email out in the public domain.I have to admit that I was a bit shocked myself with the revelations when I first read it and if he is correct then it's massively positive imo. | hjb1 | |
19/1/2017 00:43 | ok, jings better strap myself in then if that's what you're telling me. | the monkster | |
19/1/2017 00:23 | yawn yawn!, yes that's exactly what happens to me when I see your posts! lmao. Like the man says, unlikely Illumina will win, he has obviously unearthed some juicy stuff on Illumina for the legals to halt the publication ..and obviously knows more than you will ever know...about what is going on..take it on board! | hjb1 | |
19/1/2017 00:13 | yawn yawn - just pay us out some liquidation proceeds while you are able to please | the monkster | |
19/1/2017 00:06 | elrico, the "source" is from Hardman as stated , it's legit, believe it! What's with the Oct D day, the court case is July? | hjb1 | |
18/1/2017 23:59 | Post 4276 - though a welcome change from the children hurling mud at a blogger, it means nothing without a source. It could well be written by a semi literate PI. However, I do hope there is truth to it and perhaps mid 2017 we may get a broad hint how this will go ahead of October D-day. | elrico | |
10/1/2017 22:03 | Now that is very interesting! | hurricane. | |
10/1/2017 20:48 | NOTE : - For anyone with their money and heart in NIPT's future. Below is an extract of an e-mail exchange between a respected investor and someone working with Hardman........ and it should give a filip to all NIPT'rs after such a dreadful 2016. Game-changer to come in 2017 re. court battle with Illumna !! Investor (bakky) "I emailed Hardman's regarding the patent issue and his reply was very interesting.It seems the patent CAN be got around, as I said if that is the case then that is MASSIVE imo! his reply below, Dear Mr ..... First, I have undertaken a complete review of the patent situation in Europe and came to the conclusion that Illumina has a very weak case. However, I have not been allowed to publish this work because the lawyers stated that I had supplied the entire defense and did not want this in the public domain. So I think that Premaitha has a good chance of winning its case. However, I am also aware of time and costs and could understand a situation where Premaitha settles out of court on the right terms - ie close to the royalty rate that is paid by its 'friends' as opposed to the $75 per test that Illumina wants to charge Great Ormond Street Hospital. Notwithstanding this, Illumina's patents are not covered in several territories in SE Asia. This provides two things. First, it means that IONA can be used in these markets without risk of patent infringement. Secondly, it means that maternal blood samples can be spun down and analysed in, say Europe, and the results sent to Taiwan for analysis (as Yourgene is currently doing), thus avoiding Illumina's European patents. Therefore, I feel that this is a realistic possibility in the unlikely event that the Illumina patents are upheld. I hope that this helps. Dr ........ | dyfiman | |
10/1/2017 16:49 | hjb Unfortunately yes, he is still in business. My only wonder is how ADVFN allow him to continue to use their website. | blackss | |
10/1/2017 16:33 | ha ha! not a fan then? lol.Anyway does anyone pay a blind bit of notice to him nowadays? | hjb1 | |
09/1/2017 17:07 | https://latestglobal | timojelly | |
09/1/2017 12:03 | TW will be out of business I hope thanks to Aiden Earley and can go and live in his Greek hovel farming Olives. | twix386 | |
05/1/2017 12:43 | Brainspark will keep us informed of ANY good news and when it comes so will he!!! It would now be opportune to deliver any of the long, long, long awaited commercial news items. Obviously some of them, having been literally years now are clearly off the table and no-show, but those that are just month(s) late could always make a guest appearance, so Brainspark can return without missing a ramptastic beat and TW's blind faith can START to look credible rather than incredible! lol | twix386 | |
03/1/2017 08:24 | ahh brainspark, so you are alive and just hiding! stopped posting on LSE after all the ramping proved predictably incorrect numerous times and then disappeared. Quite objectionable really!! More respect if you'd acknowledged, than ran away. Even Grape had more integrity. Now just copying other people's LSE post to here instead. lol We have largely moved on from Genoma so Wakey Wakey! | twix386 | |
03/1/2017 07:59 | Wakey Wakey :@) Funding update from Esperite: As an update on the previous communication the Group announces that it has made substantial progress in its discussion with potential external investors. However, it has currently not yet reached the level that the Group can announce more details. The Group is also working on additional financing from its main shareholder. An up- date about this additional financing will be communicated in January 2017. hxxp://hugin.info/14 | brainspark1 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions